Press Releases

Press Releases

When a company develops, manufactures and delivers vaccines and therapeutics that take on the most serious global health threats, it’s not surprising to see their name in the headlines. And we are honored that for more than 20 years, Emergent has been one of those names. Included below are prominent news and feature stories that profile a range of our accomplishments through the years as well as advancements we’ve made in the technologies, processes and expertise needed to serve as a premier CDMO.

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

  • Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies,...
READ MORE

Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate

  • Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large...
READ MORE

Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability

  • Company acquires property adjacent to its Canton, Massachusetts live viral drug substance development and manufacturing...
READ MORE

Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

  • Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...
READ MORE

Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

  • CDMO agreement for NanoFlu to support pathway to licensure
  • Expanded collaboration now includes NanoFlu and COVID-19 vaccine...
READ MORE

Vaxart AGREEMENT for Experimental Oral Vaccine Candidate for Coronavirus Disease

GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered...

READ MORE
WANT MORE INFORMATION?

Learn more about Emergent CDMO’s work and the many milestones we’ve reached in our news release archive below.  If you’re a media representative, please feel free to contact us at cdmo[at]ebsi.com.

Interested in learning more about Emergent BioSolutions, Inc.? Please visit emergentbiosolutions.com.